|
- Recursion Pharmaceuticals, Inc. - MIT and Recursion Release Boltz-2 . . .
Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias
- Recursion Pharmaceuticals, Inc.
By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine
- Recursion Pharmaceuticals, Inc. - Presentations
The Investor Relations website contains information about Recursion Pharmaceuticals, Inc 's business for stockholders, potential investors, and financial analysts
- Pioneering TechBio Solutions in Drug Discovery | Recursion
Our data and the Recursion OS enable us to train intelligent machine learning models for drug discovery and development, which help us rapidly identify new targets and design highly optimized molecules that fuel our pipeline of potential first-in-class and best-in-class medicines
- Recursions Drug Discovery Pipeline | Recursion
Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of best-in-class and first-in-class therapeutic assets We focus on indications with high unmet need, including oncology and rare disease
- Recursion Reports First Quarter 2025 Financial Results and Provides . . .
Recursion and Sanofi advanced their fourth partnered program through a significant discovery milestone This milestone involved the Recursion OS identifying differentiated, orally active small molecule leads against a high-interest immune cell target
- Recursion Pharmaceuticals, Inc. - Recursion Reports Interim Phase 1 . . .
Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias
- Ben Taylor - recursion. com
Ben Taylor comes to Recursion after over 4 years as the CFO of Exscientia Ben has more than two decades of experience in healthcare investment banking and executive roles, including 15 years at Goldman Sachs and Barclays in the U S , Asia and Europe
|
|
|